Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 3, 2017, Pages

  Griffin, M Pamela ^a   Khan, Anis A ^a   Esser, Mark T ^a   Jensen, Kathryn ^a   Takas, Therese ^a   Kankam, Martin K ^b   Villafana, Tonya ^a   Dubovsky, Filip ^a  

^a MEDIMMUNE   (United States)

^b Vince and Associates Clinical Research   (United States)

Author keywords

Healthy adults; Infants; Lower respiratory tract infections; MEDI8897; Pharmacokinetics; Respiratory syncytial virus; RSV

Indexed keywords

ANTIVIRUS AGENT; MEDI 8897; MONOCLONAL ANTIBODY; PALIVIZUMAB; PLACEBO; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; VOMITING; BIOAVAILABILITY; BLOOD; BODY MASS; CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PATIENT SAFETY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BODY MASS INDEX; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE; PATIENT SAFETY; PRIMARY PREVENTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 85014082995     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01714-16     Document Type: Article

References (25)

1. Brandt CD, Kim HW, Arrobio JO, Jeffries BC, Wood SC, Chanock RM, Parrott RH. 1973. Epidemiology of respiratory syncytial virus infection in Washington, DC 3. Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol 98:355-364.
2. Glezen P, Denny FW. 1973. Epidemiology of acute lower respiratory disease in children. N Engl J Med 288:498-505. https://doi.org/10.1056/NEJM197303082881005.
3. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588-598. https://doi.org/10.1056/NEJMoa0804877.
4. Hall CB. 2012. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets 12:92-97. https://doi.org/10.2174/187152612800100099.
5. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. https://doi.org/10.1016/S0140-6736(10)60206-1.
6. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446. https://doi.org/10.1001/jama.282.15.1440.
7. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. 2012. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 31:5-9. https://doi.org/10.1097/INF.0b013e31822e68e6.
8. Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, Chetcuti PA, Shaw NJ, Woods A, Boorman J, Coles S, Turner J. 2001. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 85:463-468. https://doi.org/10.1136/adc.85.6.463.
9. Meissner HC. 2003. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 22:S40-S45. https://doi.org/10.1097/01.inf.0000053884.21238.13.
10. Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, Camargo E, Chanock RM. 1973. Epidemiology of respiratory syncytial virus infection in Washington, DC II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 98:289-300.
11. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422-434.
12. American Academy of Pediatrics. 2014. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:415-420. https://doi.org/10.1542/peds.2014-1665.
13. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-1117. https://doi.org/10.1126/science.1234914.
14. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, van Bleek GM, Widjojoatmodjo MN, Bogers WM, Mei H, Radbruch A, Scheeren FA, Spits H, Beaumont T. 2010. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 16:123-128. https://doi.org/10.1038/nm.2071.
15. Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524. https://doi.org/10.1074/jbc.M604292200.
16. Robbie GJ, Criste R, Dall'Acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. 2013. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 57:6147-6153. https://doi.org/10.1128/AAC.01285-13.
17. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. 2012. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother 56:4927-4936. https://doi.org/10.1128/AAC.06446-11.
18. MedImmune LLC. 2014. Synagis (palivizumab) injections, for intramuscular use. Full prescribing information. MedImmune LLC, Gaithersburg, MD.
19. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. 1981. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 98:708-715. https://doi.org/10.1016/S0022-3476(81)80829-3.
20. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristam DA, Siber GR, Prince GA, van Raden M, Hemming VG, Respiratory Syncytial Virus Immune Globulin Study Group. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329:1524-1530. https://doi.org/10.1056/NEJM199311183292102.
21. PREVENT Study Group. 1997. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99:93-99. https://doi.org/10.1542/peds.99.1.93.
22. The IMpact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537.
23. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. 1981. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 7:263-271. https://doi.org/10.1002/jmv.1890070403.
24. Falloon J, Ji F, Curtis C, Bart S, Sheldon E, Krieger D, Dubovsky F, Lambert S, Takas T, Villafana T, Esser MT. 2016. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine 34:2847-2854. https://doi.org/10.1016/j.vaccine.2016.04.002.
25. Patton K, Aslam S, Shambaugh C, Lin R, Heeke D, Frantz C, Zuo F, Esser MT, Paliard X, Lambert SL. 2015. Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques. Vaccine 33:4472-4478. https://doi.org/10.1016/j.vaccine.2015.07.025.